A framework for organizing and selecting quantitative approaches for benefit-harm assessment

Lignende værker

• Benefits and harms of roflumilast in moderate to severe COPD
  af: Yu, Tsung, et al.
  Udgivet: (2013)
• Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer
  af: Puhan, Milo A., et al.
  Udgivet: (2015)
• Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
  af: Puhan, Milo A., et al.
  Udgivet: (2015)
• Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
  af: Stegeman, Inge, et al.
  Udgivet: (2015)
• Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
  af: Aschmann, Hélène E, et al.
  Udgivet: (2019)